Page 2 - Prime Editing News Today

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco. The J.P. Morgan Healthcare Conference has...

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco.

CAMBRIDGE, Mass., Jan. 05, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the...

/PRNewswire/ -- Prime Medicine, Inc. (Nasdaq: PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference in San...

Modifying a patient’s DNA is no longer just for science fiction novels. The CRISPR gene editing technique developed by Jennifer Doudna and Emmanuelle Charpentier only took 10 years to reach the market as Casgevy (exagamglogene autotemcel/exa-cel, Vertex Pharmaceuticals Inc.), treating congenital pathologies such as β-thalassemia and severe sickle cell disease (SCD). But science does not stop.

Have you ever wondered what the "secrets" within the building blocks of life are? In a world where science fiction often becomes reality, the field of synthetic biology is paving the way toward unlocking these secrets. How can cutting-edge technologies propel us into a future where we manipulate life at the molecular level?To answer this

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well

We recently passed an anniversary, of sorts – one year to the day since the stock market hit bottom. On October 12 of last year, the S&P 500 reached its trough; since then, the market trend has been upward despite some volatility and a recent pullback. Brian Belski, chief investment strategist from BMO Capital, believes that we’re into a secular bull market now. Looking at a series of factors – general economic growth, the slowing pace of inflation, the stage of the Fed...